
    
      We administered 5-FU, lv and Oxaliplatin as adjuvant chemotherapy (3 weeks per cycle) to
      patients with Stage II or Stage III colorectal cancer. The study endpoints were disease-free
      survival, overall survival, and liver metastasis-free survival as evaluated by
      intent-to-treat analysis.
    
  